Saroglitazar magnesium 2 mg (DrugBank: Saroglitazar, Magnesium)
17 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 0 |
11 | 重症筋無力症 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
46 | 悪性関節リウマチ | 0 |
51 | 全身性強皮症 | 0 |
64 | 血栓性血小板減少性紫斑病 | 0 |
70 | 広範脊柱管狭窄症 | 0 |
93 | 原発性胆汁性胆管炎[原発性胆汁性肝硬変 (~2017.3)] | 1 |
97 | 潰瘍性大腸炎 | 0 |
166 | 弾性線維性仮性黄色腫 | 0 |
225 | 先天性腎性尿崩症 | 0 |
235 | 副甲状腺機能低下症 | 0 |
284 | ダイアモンド・ブラックファン貧血 | 0 |
291 | ヒルシュスプルング病(全結腸型又は小腸型) | 0 |
296 | 胆道閉鎖症 | 0 |
297 | アラジール症候群 | 0 |
298 | 遺伝性膵炎 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03112681 (ClinicalTrials.gov) | August 18, 2017 | 10/4/2017 | Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis | A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS ) | Primary Biliary Cirrhosis | Drug: Saroglitazar magnesium 2 mg;Drug: Saroglitazar magnesium 4 mg;Drug: Placebo Oral Tablet | Zydus Discovery DMCC | NULL | Active, not recruiting | 18 Years | 75 Years | All | 37 | Phase 2 | United States |